Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04903314 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
A Phase 1 study, sponsored by SK Life Science.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT04903314 is a Phase 1 study that has completed, run by SK Life Science. The registered enrollment target is 26 participants.
The verdict
NCT04903314, a Phase 1 study, has completed, sponsored by SK Life Science.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.
Interventions
- DRUG Xcopri
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2025-11-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04903314
The ClinicalTrials.gov registry entry for NCT04903314 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SK Life Science, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xcopri is the first listed.
NCT04903314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04903314 about?
NCT04903314 is a clinical study titled "Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures". The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.
What is the current status of trial NCT04903314?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2021-05-27. Estimated completion is 2025-11-06.
What interventions are being tested in trial NCT04903314?
The interventions under investigation include: Xcopri (DRUG).
Who is sponsoring clinical trial NCT04903314?
This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.